Principal Investigator
Terrence Bradley
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240439
Clinical Trial Summary
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
POIESIS: P53 activation to OptImizE responseS in myelofibrosIS
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Leukemia/heme
Contact Information
Phone Number
305-243-2647